Jane Street Group LLC Acquires 272,862 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Jane Street Group LLC boosted its stake in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 287.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 367,855 shares of the company's stock after purchasing an additional 272,862 shares during the period. Jane Street Group LLC owned about 0.16% of Sana Biotechnology worth $600,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Northern Trust Corp increased its holdings in Sana Biotechnology by 5.3% in the fourth quarter. Northern Trust Corp now owns 1,188,346 shares of the company's stock valued at $1,937,000 after purchasing an additional 60,004 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in Sana Biotechnology in the fourth quarter valued at $182,000. Virtus ETF Advisers LLC increased its holdings in Sana Biotechnology by 170.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 34,849 shares of the company's stock valued at $57,000 after purchasing an additional 21,959 shares during the period. Coldstream Capital Management Inc. acquired a new stake in Sana Biotechnology in the fourth quarter valued at $57,000. Finally, Syon Capital LLC acquired a new stake in Sana Biotechnology in the fourth quarter valued at $27,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SANA has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $11.00 price target on shares of Sana Biotechnology in a research report on Thursday, April 24th. Jefferies Financial Group initiated coverage on shares of Sana Biotechnology in a research report on Friday, March 14th. They set a "buy" rating and a $7.00 price target on the stock. Finally, Citizens Jmp raised shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target on the stock in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $10.80.

Sana Biotechnology Stock Down 4.8%

SANA traded down $0.11 during trading on Friday, reaching $2.16. 4,703,731 shares of the stock traded hands, compared to its average volume of 3,477,170. The stock has a market capitalization of $487.03 million, a PE ratio of -1.54 and a beta of 1.75. The stock's 50-day moving average is $1.76 and its 200 day moving average is $2.33. Sana Biotechnology, Inc. has a 12 month low of $1.26 and a 12 month high of $8.17.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. As a group, equities research analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.